Research
Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer?
The Brief
- MedPage Today published a video preview by Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care, on the phase III SWOG-S1418/NRG Oncology BR006 trial.
- The trial studies adjuvant pembrolizumab (Keytruda) in triple-negative breast cancer.
- The source is a short preview snippet and does not report the trial's results.
Why it matters
Triple-negative breast cancer is an aggressive subtype with limited targeted options, so results from a phase III trial of adjuvant pembrolizumab could bear on post-surgery treatment decisions.
Who’s affected
- oncologists and breast cancer clinicians
- patients with triple-negative breast cancer and their families
- #breast cancer
- #immunotherapy
- #clinical trials
- #oncology
- #pembrolizumab
(MedPage Today) -- In this exclusive MedPage Today video, Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care in California, previews findings from the phase III SWOG-S1418/NRG Oncology BR006 trial of adjuvant pembrolizumab (Keytruda) in...